Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Anticipated Size Of The Tuberculosis Therapeutics Market Over The Five-Year Period 2025–2029?
The tuberculosis therapeutics market size has experienced strong growth in recent years. It is projected to increase from $1.88 billion in 2024 to $2 billion in 2025, at a compound annual growth rate (CAGR) of 6.6%. This historical growth can be attributed to factors such as the rising incidence of tuberculosis, the growing adoption of tuberculosis therapeutics, increased awareness regarding tuberculosis (TB), the escalating incidence of XDR-TB, and the expanding incidence of drug-resistant tuberculosis.
The tuberculosis therapeutics market size is projected to experience substantial growth over the next few years. Its valuation is anticipated to reach $2.55 billion by 2029, achieving a compound annual growth rate (CAGR) of 6.2%. This anticipated growth during the forecast period is attributable to several factors, including heightened investments in healthcare infrastructure, increased public awareness and educational initiatives, an uptick in research and development funding, a surge in product approvals for various anti-TB agents, and the expanding elderly population. Key trends expected within this period encompass progress in drug development, the adoption of personalized medicine, the use of combination therapies, the integration of digital health solutions, and the application of artificial intelligence and machine learning in drug discovery processes.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20983&type=smp
Which Major Market Drivers Are Shaping The Future Of The Tuberculosis Therapeutics Market?
The increasing incidence of TB-HIV co-infection rates is projected to drive the expansion of the tuberculosis therapeutics market in the foreseeable future. TB-HIV co-infection rates refer to the proportion of individuals simultaneously afflicted with both tuberculosis and the human immunodeficiency virus. These escalating co-infection rates emerge due to the compromised immune system caused by HIV, which heightens an individual’s vulnerability to tuberculosis, alongside the global convergence of both epidemics in high-risk groups. Tuberculosis therapeutics assist in managing rising TB-HIV co-infection rates by delivering targeted treatments that address both TB infection and HIV-related immune suppression, ultimately improving patient recovery and alleviating the burden of both diseases. For instance, in October 2023, information from gov.uk, a UK-based public sector body, indicated that England recorded 3,805 new HIV diagnoses in 2022, signifying a 22% increase from the 3,118 cases reported in 2021. Therefore, the growing TB-HIV co-infection rates are propelling the growth of the tuberculosis therapeutics market.
What Are The Emerging Segments Gaining Attention In The Tuberculosis Therapeutics Market?
The tuberculosis therapeuticsmarket covered in this report is segmented –
1) By Type: Active Tuberculosis (TB); Latent Tuberculosis (TB)
2) By Product Type: Isoniazid; Rifampin; Pyrazinamide; Hydrazine derivatives; Miscellaneous anti-tubercular drugs; Ethambutol
3) By Route of Administration: Oral; Parenteral; Other route of administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol); Second-Line Drugs (Fluoroquinolones, Aminoglycosides); Combination Therapies; Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis; Rifampicin-Based Regimens; Rifapentine-Based Regimens; Combination Prophylactic Therapies
What Trends Are Expected To Drive The Tuberculosis Therapeutics Market?
Leading companies in the tuberculosis therapeutics market are concentrating on developing advanced solutions, such as combination therapy, to elevate treatment effectiveness, shorten the course of therapy, and fight drug-resistant strains of tuberculosis. Combination therapy involves utilizing two or more medications from different categories to manage a disease, with the aim of increasing efficacy, reducing resistance, and improving patient outcomes. As an illustration, in July 2024, Johnson & Johnson, a US-based pharmaceutical company, reached a notable achievement in tuberculosis treatment with the approval of SIRTURO (bedaquiline) by both the U.S. FDA and the European Commission. This pioneering drug represents the first in over four decades specifically engineered to target multidrug-resistant tuberculosis (MDR-TB). Its distinctive mechanism of action, which inhibits the ATP synthase enzyme vital for TB bacteria’s energy production, consequently offers a focused and potent therapeutic method. Incorporating it into combination therapies considerably improves the overall efficacy of MDR-TB regimens, thereby decreasing treatment duration and enhancing patient compliance.
Which Leading Players Are Enhancing Their Tuberculosis Therapeutics Market Presence Worldwide?
Major companies operating in the tuberculosis therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/tuberculosis-therapeutics-global-market-report
Which Global Regions Are Influencing The Competitive Landscape Of The Tuberculosis Therapeutics Market?
North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Tuberculosis Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=20983&type=smp
Browse Through More Reports Similar to the Global Tuberculosis Therapeutics Market 2025, By The Business Research Company
Traffic Signals Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/traffic-signals-global-market-report
Space Traffic Management Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/space-traffic-management-global-market-report
Vessel Traffic Management Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/vessel-traffic-management-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model